- Home
- KOD vs ETON Comparison
KOD vs ETON Comparison
Compare KOD & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- ETON
- Stock Information
- Founded
- KOD 2009
- ETON 2017
- Country
- KOD United States
- ETON United States
- Employees
- KOD N/A
- ETON N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- ETON Health Care
- Exchange
- KOD Nasdaq
- ETON Nasdaq
- Market Cap
- KOD 186.3M
- ETON 199.5M
- IPO Year
- KOD 2018
- ETON 2018
- Fundamental
- Price
- KOD $8.72
- ETON $12.58
- Analyst Decision
- KOD Hold
- ETON Strong Buy
- Analyst Count
- KOD 5
- ETON 2
- Target Price
- KOD $6.80
- ETON $15.00
- AVG Volume (30 Days)
- KOD 484.9K
- ETON 235.4K
- Earning Date
- KOD 11-14-2024
- ETON 11-12-2024
- Dividend Yield
- KOD N/A
- ETON N/A
- EPS Growth
- KOD N/A
- ETON N/A
- EPS
- KOD N/A
- ETON N/A
- Revenue
- KOD N/A
- ETON $34,677,000.00
- Revenue This Year
- KOD N/A
- ETON $23.05
- Revenue Next Year
- KOD N/A
- ETON $81.27
- P/E Ratio
- KOD N/A
- ETON N/A
- Revenue Growth
- KOD N/A
- ETON 5.64
- 52 Week Low
- KOD $2.19
- ETON $3.03
- 52 Week High
- KOD $11.60
- ETON $13.98
- Technical
- Relative Strength Index (RSI)
- KOD 64.72
- ETON 61.05
- Support Level
- KOD $8.03
- ETON $11.80
- Resistance Level
- KOD $9.55
- ETON $13.01
- Average True Range (ATR)
- KOD 0.89
- ETON 0.70
- MACD
- KOD -0.08
- ETON -0.14
- Stochastic Oscillator
- KOD 36.51
- ETON 68.46
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.